Overview

SU5416 in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Semaxinib